Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, IH | - |
dc.contributor.author | Park, YT | - |
dc.contributor.author | Roh, K | - |
dc.contributor.author | Chung, H | - |
dc.contributor.author | Kwon, IC | - |
dc.contributor.author | Jeong, SY | - |
dc.date.accessioned | 2024-01-21T05:33:49Z | - |
dc.date.available | 2024-01-21T05:33:49Z | - |
dc.date.created | 2021-09-03 | - |
dc.date.issued | 2005-02-02 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/136742 | - |
dc.description.abstract | Stable paclitaxel/Lipiodol solutions as well as emulsions were developed for the treatment of solid tumors including hepatocellular carcinoma. Paclitaxel could be dissolved in Lipiodol, an oily contrast medium, but precipitated out and formed aggregates with time. Paclitaxel precipitation was due to the inter- and intra-molecular hydrogen bonding of paclitaxel molecules. Time-dependent paclitaxel aggregation was completely prevented by adding small amounts of additional solvents, which are miscible with Lipiodol. It was also notable that paclitaxel helped in stabilizing the water-in-oil (w/o) type emulsion of Lipiodol and lopamiro. The stability, physical properties and in vitro drug release profiles of the stable paclitaxel solutions and emulsions were characterized. When the stable oily paclitaxel solution was used for the treatment of B16F10 melanoma in C57BL/6 mice, the malignant cells were eradicated completely in 2 weeks, whereas the solid tumor grew rapidly and metastasized to the thigh and to other organs in the control group. Also, the mice survived for more than 1 year after the paclitaxel treatment, whereas all of those in the control group died in 40 days. (C) 2004 Elsevier B.V. All rights reserved. | - |
dc.language | English | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION | - |
dc.subject | ANTITUMOR AGENTS | - |
dc.subject | ANTICANCER AGENT | - |
dc.subject | HEPATOMA | - |
dc.subject | TAXOL | - |
dc.subject | LIPIODOL | - |
dc.subject | DELIVERY | - |
dc.subject | CANCER | - |
dc.subject | MICROSPHERES | - |
dc.subject | METASTASES | - |
dc.title | Stable paclitaxel formulations in oily contrast medium | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jconrel.2004.10.023 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CONTROLLED RELEASE, v.102, no.2, pp.415 - 425 | - |
dc.citation.title | JOURNAL OF CONTROLLED RELEASE | - |
dc.citation.volume | 102 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 415 | - |
dc.citation.endPage | 425 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000226628100008 | - |
dc.identifier.scopusid | 2-s2.0-11844255661 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION | - |
dc.subject.keywordPlus | ANTITUMOR AGENTS | - |
dc.subject.keywordPlus | ANTICANCER AGENT | - |
dc.subject.keywordPlus | HEPATOMA | - |
dc.subject.keywordPlus | TAXOL | - |
dc.subject.keywordPlus | LIPIODOL | - |
dc.subject.keywordPlus | DELIVERY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | MICROSPHERES | - |
dc.subject.keywordPlus | METASTASES | - |
dc.subject.keywordAuthor | paclitaxel | - |
dc.subject.keywordAuthor | lipiodol | - |
dc.subject.keywordAuthor | oily contrast medium | - |
dc.subject.keywordAuthor | emulsion | - |
dc.subject.keywordAuthor | cancer | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.